Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have garnered considerable attention for the management of overweight/obesity and type 2 diabetes mellitus. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.